Oruka Therapeutics (ORKA) Expected to Announce Quarterly Earnings on Monday

Oruka Therapeutics (NASDAQ:ORKA) is projected to announce its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect the company to post earnings of ($0.5125) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. On average, analysts expect Oruka Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oruka Therapeutics Stock Down 4.1%

Shares of ORKA opened at $92.56 on Monday. Oruka Therapeutics has a 12-month low of $12.84 and a 12-month high of $99.00. The firm has a market capitalization of $5.58 billion, a price-to-earnings ratio of -48.20 and a beta of -0.35. The stock’s 50-day moving average price is $78.73 and its 200 day moving average price is $57.96.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ORKA. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research note on Monday. Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. UBS Group upped their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, Piper Sandler restated an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Insider Buying and Selling

In other Oruka Therapeutics news, Director Carl Dambkowski sold 105,000 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the transaction, the director owned 73,743 shares of the company’s stock, valued at approximately $4,348,624.71. This represents a 58.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the transaction, the chief executive officer directly owned 925,580 shares in the company, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 188,406 shares of company stock worth $12,019,683. Corporate insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its stake in Oruka Therapeutics by 777.1% in the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company’s stock valued at $4,338,000 after buying an additional 126,803 shares during the period. Virtus Investment Advisers LLC bought a new position in shares of Oruka Therapeutics during the fourth quarter worth approximately $267,000. RTW Investments LP lifted its holdings in Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after purchasing an additional 112,499 shares during the last quarter. Millennium Management LLC bought a new stake in Oruka Therapeutics in the 4th quarter valued at $1,780,000. Finally, Janus Henderson Group PLC bought a new stake in Oruka Therapeutics in the 4th quarter valued at $367,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.